Supernus Pharmaceuticals logo

Supernus PharmaceuticalsNASDAQ: SUPN

Profile

Sector:

Healthcare

Country:

United States

IPO:

01 May 2012

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$2.04 B
-11%vs. 3y high
81%vs. sector
412.95
0%vs. 3y high
98%vs. sector
-18%vs. 3y high
59%vs. sector
-6%vs. 3y high
49%vs. sector

Price

after hours | Tue, 05 Nov 2024 00:57:35 GMT
$37.00+$3.69(+11.08%)

Dividend

No data over the past 3 years
$168.32 M$157.30 M
$168.32 M$19.92 M

Analysts recommendations

Institutional Ownership

SUPN Latest News

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript
seekingalpha.com04 November 2024 Sentiment: -

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief Executive Officer Tim Dec – Chief Financial Officer Conference Call Participants Andrew Tsai – Jefferies Stacy Ku – TD Cowen David Amsellem – Piper Sandler Operator Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com04 November 2024 Sentiment: -

Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
globenewswire.com21 October 2024 Sentiment: POSITIVE

ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2024 after the market closes on Monday, November 4, 2024.

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
globenewswire.com17 October 2024 Sentiment: POSITIVE

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression Company to host webcast today at 4:30 p.m. ET to discuss the topline data Topline results from Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression expected first-half 2025 ROCKVILLE, Md.

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
globenewswire.com10 October 2024 Sentiment: POSITIVE

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder.

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
globenewswire.com24 September 2024 Sentiment: POSITIVE

ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night host, and mom, Busy Philipps, is speaking up this fall about her ongoing journey with attention-deficit/hyperactivity disorder (ADHD), bringing awareness to the often-overlooked symptoms of the condition in women and Qelbree, a non-stimulant ADHD treatment that has benefitted her.

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
seekingalpha.com11 September 2024 Sentiment: POSITIVE

Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio includes key drugs like Qelbree for ADHD and GOCOVRI for Parkinson's, with Qelbree's revenues being potentially seasonally influenced. Despite falling sales of older drugs, Supernus' strong financial position and promising pipeline, including SPN-820 for depression, suggest significant future upside is achievable, but not inevitable.

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
benzinga.com11 September 2024 Sentiment: NEGATIVE

Piper Sandler downgraded Supernus Pharmaceuticals Inc SUPN, saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected.

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
globenewswire.com28 August 2024 Sentiment: POSITIVE

ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts.

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
zacks.com09 August 2024 Sentiment: POSITIVE

The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • 1(current)
  • 2

What type of business is Supernus Pharmaceuticals?

Supernus Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Rockville, Maryland, specializing in the development and commercialization of drugs for the treatment of central nervous system (CNS) disorders in neurology and psychiatry. It was founded in 2005. The company's product portfolio includes several commercialized drugs, as well as products at various stages of development: Oxtellar XR and Trokendi XR - the first extended-release formulations of oxcarbazepine and topiramate for once-daily use, intended for the treatment of epilepsy. Several patented CNS products are in development - SPN-812 (viloxazine hydrochloride), SPN-604 (extended-release oxcarbazepine) for the treatment of bipolar disorder, SPN-817 for the treatment of severe pediatric epilepsy disorders, SPN-809 for the treatment of depression.

What sector is Supernus Pharmaceuticals in?

Supernus Pharmaceuticals is in the Healthcare sector

What industry is Supernus Pharmaceuticals in?

Supernus Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is Supernus Pharmaceuticals from?

Supernus Pharmaceuticals is headquartered in United States

When did Supernus Pharmaceuticals go public?

Supernus Pharmaceuticals initial public offering (IPO) was on 01 May 2012

What is Supernus Pharmaceuticals website?

https://www.supernus.com

Is Supernus Pharmaceuticals in the S&P 500?

No, Supernus Pharmaceuticals is not included in the S&P 500 index

Is Supernus Pharmaceuticals in the NASDAQ 100?

No, Supernus Pharmaceuticals is not included in the NASDAQ 100 index

Is Supernus Pharmaceuticals in the Dow Jones?

No, Supernus Pharmaceuticals is not included in the Dow Jones index

When was Supernus Pharmaceuticals the previous earnings report?

No data

When does Supernus Pharmaceuticals earnings report?

Next earnings report date is not announced yet